



24th February 2020

dorsaVi signs a second stage evaluation agreement with Stryker to assess technology outputs with clinicians

Melbourne, Australia, 24th February 2020; dorsaVi (ASX: DVL) today announced that it has signed a second stage six month evaluation agreement with Stryker Leibinger GmbH & Co. KG (Stryker) in which Stryker's staff will utilise and evaluate dorsaVi's sensors, software and algorithms to assess patients and share this data with leading clinicians.

During this second agreement, Stryker will use the algorithms evaluated in the initial project over a minimum of 6 months, gaining access to dorsaVi's proprietary software, sensors and algorithms.

Stryker Leibinger GmbH & Co. KG is the German subsidiary of Stryker Corporation, a Fortune 500 company and one of the world's leading medical technology companies.

dorsaVi Chief Executive Officer Dr Andrew Ronchi said: "We are excited to be able to secure the second stage of this project and allow Stryker to capture data insights from real patients and explore the relevance of this data in improving the management of patients with orthopaedic conditions. We are pleased that Stryker, one of the most innovative medical device companies in the world, has chosen to continue its evaluation of dorsaVi's sensor technology."

- ENDS -

For more information about dorsaVi or to arrange an interview, please contact:

Andrew Ronchi
CEO dorsaVi
+61 417 882 267
+1 858 333 9446
ar@dorsavi.com

Matt May
GM dorsaVi
+61 409 324 949
mmay@dorsavi.com

The release of this announcement was authorised by Andrew Ronchi, CEO.

For personal use only

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Occupational Health and Safety (OHS):** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions - ViMove, ViMove2 and Professional Suite – which provide objective assessment, monitoring outside the clinic and immediate biofeedback. dorsaVi is currently used by medical and physiotherapy practices globally.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used in the US by the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL), by the AFL and NRL clubs and by Barclays Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally.

Further information is available at www.dorsavi.com